Blinatumomab belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.<\/p>\n
Blinatumomab is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.\u00a0If Blinatumomab for Injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN.<\/strong>\u00a0For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query.\u00a0Like 1. How to get access in in India. 2. Medicine Price. 3. Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia. 4. Ensuring 100% transparency.\u00a0<\/strong><\/p>\n Blinatumomab for Injection can be made available to patients, doctors, and hospitals in Mumbai, Delhi, Kolkata, Bhubaneswar, Bangalore, Hyderabad, Chennai, Ahmedbad, Pune, Surat, Visakhapatnam, Jaipur, Lucknow, Nagpur, Indore, Patna, Agartala, Guwahati, Imphal, Kohima, Namchi, Noida, Ghaziabad, Ludhiana, Agra, Varanasi, Srinagar, Amritsar, Jodhpur, Chandigarh, Gurgaon, Gorakhpur, Dehradun, Jammu, Hyderabad, Thiruvananthapuram, Kochi, Coimbatore, Puducherry, Mysuru, Salem, Vellore, Tiruppur, Guntur, Goa, Kolhapur, Mumbai, Nashik, and various other regions in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.<\/p>\n To receive comprehensive support, please call us at\u00a09811747774<\/a>,\u00a09891296838<\/a>\u00a0or WhatsApp at\u00a09811747774<\/a>,\u00a09891296838\u00a0<\/a>or email us at\u00a0info@indianpharmanetwork.co.in\u00a0<\/a>\u00a0for Blinatumomab for Injection in India.<\/strong><\/p>\n Note:<\/strong><\/em> Blinatumomab For Injection is “used to treat adults and children with: \u2022 B-cell precursor acute lymphoblastic leukemia (ALL)<\/strong>“. BLINCYTO for injection is a<\/strong> “prescription medicine”<\/strong>. It is available in “form and strength”<\/strong> For injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution.\u00a0 BLINCYTO for injection<\/strong>\u00a0can be obtained in India upon request.<\/strong> Approval Date:<\/strong> 2014BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014<\/h4>\n
Related posts for product review usage<\/h3>\n
\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"Blinatumomab For Injection
\nfor intravenous use Initial U.S. Approval: 2014<\/h2>\n
\nTo inquire about the BLINCYTO (blinatumomab) for injection \u201coffer price in India\u201d<\/strong>, \u201cshipping process\u201d<\/strong>, and the \u201cestimated time of availability in India\u201d<\/strong>, please get in touch at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.\u201d<\/p>\nFacts about your medicine<\/strong><\/h4>\n
\nProprietary Name:<\/strong> On Request
\nActive Ingredient(s):<\/strong> Blinatumomab for injection
\nDosage Forms And Strengths: For injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution.\u00a0<\/strong>
\nManufacturer: Amgen Inc<\/strong>
\nMedicine Approved By: –<\/strong> European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:\u00a0<\/strong>Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n